Related Experiment Video
Updated: May 28, 2026

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
Neuropilin-1 expression in cancer and development
Adrian M Jubb1, Laura A Strickland, Scot D Liu
1Department of Pathology, Genentech Inc, South San Francisco, CA 94080, USA. adrianj@gene.com
Neuropilin-1 (NRP1) is crucial for tumor growth and angiogenesis. Blocking NRP1 shows promise in suppressing tumors and inhibiting blood vessel formation, validating it as an anti-cancer target.
Area of Science:
- Oncology
- Vascular Biology
- Molecular Biology
Background:
- Neuropilin-1 (NRP1) acts as a co-receptor for vascular endothelial growth factor (VEGF).
- Preclinical studies indicate that blocking NRP1 can inhibit tumor growth by suppressing angiogenesis and tumor cell proliferation.
- A humanized monoclonal antibody targeting NRP1 is under clinical investigation for cancer therapy.
Purpose of the Study:
- To systematically characterize the in situ expression of NRP1 in human cancers and during mammalian development.
- To validate NRP1 as a therapeutic target for anti-angiogenesis and direct anti-tumor effects.
Main Methods:
- Generated and validated a monoclonal antibody for human NRP1 using immunohistochemistry, western blotting, immunofluorescence, and in situ hybridization.
- Assessed NRP1 expression in 65 primary breast, 95 colorectal, and 90 lung carcinomas, plus 59 metastases and 16 xenografts.
- Evaluated NRP1 in mouse embryos and a postnatal mouse trachea angiogenesis model.
Main Results:
- NRP1 immunoreactivity was detected in vessels of normal tissues adjacent to tumors and in 98-100% of all evaluated carcinomas.
- Tumor cell expression of NRP1 was observed in 36% of lung and 6% of breast carcinomas, but not in colorectal adenocarcinomas.
- In a mouse model, NRP1 blockade led to defective angiogenesis, mirroring anti-VEGF treatment effects.
Conclusions:
- NRP1 is widely expressed in tumor vasculature and, in a subset of cancers, on tumor cells, confirming its role in both angiogenesis and direct tumor cell targeting.
- NRP1 blockade effectively inhibits angiogenesis, supporting its validation as an anti-angiogenic target in malignancy.
- The study confirms NRP1's role in physiological, VEGF-mediated angiogenesis and its potential as a direct anti-tumor target in specific cancer types.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

